Quantum-Si (NASDAQ:QSI) Issues Earnings Results

Key Points

• Quantum-Si beat EPS expectations in its latest quarter, reporting a loss of $0.10 per share versus the expected $0.12 loss, though revenue came in below estimates at $0.26 million.
• Proteus reached an important technical milestone as the company completed sequencing on fully integrated instruments detecting 17 amino acids, with management targeting 18 by the end of 2026 and full sequencing kit availability in 2027.
• Liquidity remains solid despite weak near-term sales, with $190.4 million in cash and investments at quarter-end and a projected runway into Q2 2028, while 2026 revenue is expected to stay around $1 million as customers wait for Proteus.

Quantum-Si (NASDAQ:QSI - Get Free Report) issued its earnings results on Thursday. The company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.02, FiscalAI reports. The firm had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.30 million. Quantum-Si had a negative net margin of 5,605.88% and a negative return on equity of 46.05%.

Here are the key takeaways from Quantum-Si's conference call:

• Proteus reached a major technical milestone — Quantum-Si completed sequencing on fully integrated Proteus instruments detecting 17 amino acids and expects 18 by end-2026 with detection of all 20 during 2026 and a full sequencing kit in 2027, which management frames as a significant de‑risking versus Platinum.
• Early customer evaluations and commercial preparation look constructive — a prototype customer reported ~2x average read length and more amino acids detected versus Platinum, the company is running Proteus Roadshows and plans broader sample evaluations to build a buyer funnel, and has positioned Proteus at $425,000 versus >$1M for comparable high-end mass spec alternatives.
• Financial position supports the plan — Quantum‑Si had $190.4M in cash and investments at 3/31/26 and guides 2026 adjusted OpEx ≤ $98M and cash use ≤ $93M, projecting runway into Q2 2028 to fund Proteus completion and launch readiness.
• Near‑term revenue will remain limited — Q1 revenue was only $258k and the company reiterates 2026 revenue around ≈ $1M, describing 2026 as a transition year with modest capital sales as customers delay purchases pending Proteus availability.

Quantum-Si Price Performance

NASDAQ QSI traded down $0.07 during trading on Friday, reaching $0.91. The company's stock had a trading volume of 13,112,028 shares, compared to its average volume of 6,228,345. The stock has a market capitalization of $196.16 million, a PE ratio of -1.78 and a beta of 3.15. The firm has a fifty day moving average of $0.90 and a 200 day moving average of $1.20. Quantum-Si has a one year low of $0.69 and a one year high of $3.10.

Analyst Upgrades and Downgrades

QSI has been the subject of a number of analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Quantum-Si in a research report on Friday, March 27th. Canaccord Genuity Group decreased their target price on shares of Quantum-Si from $1.50 to $1.00 and set a "hold" rating on the stock in a report on Wednesday, March 4th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Quantum-Si presently has an average rating of "Hold" and a consensus price target of $3.25.

Insiders Place Their Bets

In other Quantum-Si news, Director Paula Dowdy purchased 109,890 shares of the company's stock in a transaction dated Thursday, March 5th. The stock was purchased at an average price of $0.95 per share, for a total transaction of $104,395.50. Following the transaction, the director owned 269,107 shares in the company, valued at $255,651.65. The trade was a 69.02% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Jeffrey Alan Hawkins sold 83,712 shares of Quantum-Si stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $1.01, for a total value of $84,549.12. Following the sale, the chief executive officer owned 3,776,135 shares of the company's stock, valued at approximately $3,813,896.35. This trade represents a 2.17% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 212,904 shares of company stock worth $205,021. Insiders own 22.04% of the company's stock.

Institutional Investors Weigh In On Quantum-Si

Several hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC bought a new stake in Quantum-Si during the fourth quarter valued at approximately $262,000. Invesco Ltd. lifted its holdings in shares of Quantum-Si by 36.2% during the 4th quarter. Invesco Ltd. now owns 402,821 shares of the company's stock worth $443,000 after acquiring an additional 107,093 shares during the last quarter. XTX Topco Ltd lifted its holdings in shares of Quantum-Si by 206.9% during the 4th quarter. XTX Topco Ltd now owns 461,982 shares of the company's stock worth $508,000 after acquiring an additional 311,450 shares during the last quarter. Quadrature Capital Ltd bought a new stake in shares of Quantum-Si during the 4th quarter worth $305,000. Finally, Barclays PLC lifted its holdings in shares of Quantum-Si by 21.8% during the 4th quarter. Barclays PLC now owns 269,415 shares of the company's stock worth $296,000 after acquiring an additional 48,205 shares during the last quarter. 39.90% of the stock is currently owned by institutional investors.

Quantum-Si Company Profile

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.